Vitrolife Stock Price, News & Analysis

Vitrolife has appointed members to its election committee ahead of the Annual General Meeting on April 27, 2023. The committee includes Niels Jacobsen from William Demant Invest A/S, Patrik Tigerschiöld from Bure Equity AB, and Erika Henriksson from EQT VIII, along with Chairman Jón Sigurdsson. These appointments align with guidelines set at the previous year's meeting. Shareholders can propose agenda items by submitting requests to the Board by mid-March 2023.

Thomas Axelsson, CEO of Vitrolife AB, announced his intention to retire, prompting the Board of Directors to begin the search for a successor. Axelsson has served as CEO since 2011, leading the company through profitable growth and significant value creation. Jon Sigurdsson, Chairman of the Board, will oversee the CEO recruitment process while Axelsson remains in his role until a new leader is appointed. The transition aims to ensure consistency and continuity within the organization. Vitrolife Group specializes in medical devices and genetic services to enhance fertility treatments.

VITROLIFE AB reported substantial growth in its Q2 and first half of 2022 financial results, with sales reaching SEK 829 million, a 117% year-on-year increase. Of this growth, 80% was attributed to acquisitions. Net income rose to SEK 130 million with earnings per share of SEK 0.96. The Americas saw remarkable sales growth of 241%.

However, EBITDA margin slightly decreased to 32.9% from 35.2% in Q2. For the first half, total sales reached SEK 1,581 million, with EBITDA margin also falling to 31.7%.

Vitrolife invites participants to its conference call on July 15, 2022, at 10:00 a.m. CET to discuss the interim report for January – June 2022. The call will feature Thomas Axelsson, CEO, and Patrik Tolf, CFO. Interested parties can register 10-15 minutes before the start time using provided dial-in numbers. A press release detailing the interim report will be accessible at 8:00 a.m. CET on the same day. A recorded version of the call will be available for seven days afterward.

VITROLIFE AB reported a strong first quarter for 2022, with sales reaching SEK 752 million, an increase of 98%. Key drivers included 74% growth from acquisitions and 11% organic growth. All regions saw strong performance, particularly the Americas at 255%. EBITDA rose to SEK 228 million with a margin of 30.4%, while net income was SEK 82 million, down from SEK 119 million year-over-year. Adjusted sales, excluding Covid-related business, increased by 18%.

Vitrolife invites stakeholders to a conference call on April 22, 2022, at 10:00 a.m. CET for the presentation of its interim report for January-March 2022. Dial-in details are provided for Sweden and internationally, with a conference ID of 6938009. The interim report will be released at 8:00 a.m. CET on the same day, and presentation materials will be accessible on the company’s website. A recorded version of the call will be available for seven days post-event. Contact for inquiries is Patrik Tolf, CFO.

On March 30, 2022, Vitrolife published its Annual Report for 2021, detailing the company's financial performance and strategic initiatives. The report is accessible via their website and printed copies will be mailed to shareholders who have requested them starting the week of April 11. Patrik Tolf, the CFO, can be contacted for further inquiries. This announcement seeks to inform stakeholders about the company's financial status and maintain transparency with shareholders.

The Annual General Meeting of Vitrolife AB is scheduled for April 27, 2022, at 4:00 PM in Gothenburg, Sweden. Shareholders must register by April 19, 2022, and confirm attendance by April 21, 2022. Key proposals include a dividend of SEK 0.80 per share and the election of six Board members, including re-election of Jón Sigurdsson as Chairman. The proposed Board fee totals SEK 3,600,000, revealing an increase from the previous year. The meeting will also address amendments to the Articles of Association and authorize share issues and acquisitions.

The Board of Directors of Vitrolife AB has announced the date for its Annual General Meeting, to be held on April 27, 2022, at 4:00 PM in Gothenburg, Sweden. A formal notice will be published by March 30, 2022. This meeting provides shareholders with the opportunity to participate in decisions regarding company operations and governance.